Cardiomyopathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with cardiac amyloidosis (a condition where abnormal proteins build up in the heart) confirmed by current medical standards
Who may not be able to join:
- You do not wish to take part in the trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Daniel Lavall, MD, University of Leipzig
Phone: +493419712650
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
All-cause and cardiac mortality; Cumulative rate of patients with worsening heart failure; Rate of any hospitalizations; Change in left ventricular ejection fraction; Change in left ventricular wall thickness; Change in systolic arterial pressure; Change in T1 values; Change in extracellular volume values; Change in N-Terminal Pro-B-Type Natriuretic Peptide over time; Change in high-sensitivity cardiac troponin T over time; Changes in medical treatment for heart failure
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.